We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that United Therapeutics (UTHR - Free Report) will announce quarterly earnings of $6.10 per share in its forthcoming report, representing an increase of 39.9% year over year. Revenues are projected to reach $725.32 million, increasing 18% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some United Therapeutics metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenues- Adcirca' of $6.10 million. The estimate points to a change of -10.3% from the year-ago quarter.
The consensus estimate for 'Revenues- Orenitram' stands at $109.01 million. The estimate points to a change of +29.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Remodulin' will likely reach $117.28 million. The estimate indicates a year-over-year change of +1.9%.
According to the collective judgment of analysts, 'Revenues- Tyvaso' should come in at $425.28 million. The estimate points to a change of +99% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Unituxin' will reach $59.93 million. The estimate suggests a change of +10.6% year over year.
Analysts' assessment points toward 'Revenues- Rest-of-World' reaching $30.17 million. The estimate points to a change of +4.7% from the year-ago quarter.
Analysts predict that the 'Revenues- United States' will reach $681.36 million. The estimate indicates a change of +16.3% from the prior-year quarter.
Over the past month, United Therapeutics shares have recorded returns of -2.6% versus the Zacks S&P 500 composite's -0.5% change. Based on its Zacks Rank #4 (Sell), UTHR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Analysts on Wall Street project that United Therapeutics (UTHR - Free Report) will announce quarterly earnings of $6.10 per share in its forthcoming report, representing an increase of 39.9% year over year. Revenues are projected to reach $725.32 million, increasing 18% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some United Therapeutics metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenues- Adcirca' of $6.10 million. The estimate points to a change of -10.3% from the year-ago quarter.
The consensus estimate for 'Revenues- Orenitram' stands at $109.01 million. The estimate points to a change of +29.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Remodulin' will likely reach $117.28 million. The estimate indicates a year-over-year change of +1.9%.
According to the collective judgment of analysts, 'Revenues- Tyvaso' should come in at $425.28 million. The estimate points to a change of +99% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Unituxin' will reach $59.93 million. The estimate suggests a change of +10.6% year over year.
Analysts' assessment points toward 'Revenues- Rest-of-World' reaching $30.17 million. The estimate points to a change of +4.7% from the year-ago quarter.
Analysts predict that the 'Revenues- United States' will reach $681.36 million. The estimate indicates a change of +16.3% from the prior-year quarter.
View all Key Company Metrics for United Therapeutics here>>>
Over the past month, United Therapeutics shares have recorded returns of -2.6% versus the Zacks S&P 500 composite's -0.5% change. Based on its Zacks Rank #4 (Sell), UTHR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>